Literature DB >> 28344852

Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.

Kellie N Smith1, Robbie B Mailliard2, Charles R Rinaldo3.   

Abstract

Despite the success of combination antiretroviral therapy (cART), a latent viral reservoir persists in HIV-1-infected persons. Unfortunately, endogenous cytotoxic T lymphocytes (CTLs) are unable to control viral rebound when patients are removed from cART. A "kick and kill" strategy has been proposed to eradicate this reservoir, whereby infected T cells are induced to express viral proteins via latency-inducing drugs followed by their elimination by CTLs. It has yet to be determined if stimulation of existing HIV-1-specific CTL will be sufficient, or if new CTLs should be primed from naïve T cells. In this review, we propose that dendritic cells (DCs), the most potent antigen presenting cells, act as dog trainers and can induce T cells (the dogs) to do magnificent tricks. We propose the hypothesis that an HIV-1 cure will require targeting of naïve T cells and will necessitate "teaching new dogs new tricks" while avoiding activation of potentially dysfunctional endogenous memory CTLs (letting the sleeping dogs lie).

Entities:  

Keywords:  CTL; HIV-1; dendritic cells; immunotherapy

Year:  2015        PMID: 28344852      PMCID: PMC5363401          DOI: 10.1615/ForumImmunDisTher.2016014160

Source DB:  PubMed          Journal:  For Immunopathol Dis Therap        ISSN: 2151-8017


  93 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

Review 2.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

3.  CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.

Authors:  Uma Malhotra; Claire Huntsberry; Sarah Holte; Jean Lee; Lawrence Corey; M Juliana McElrath
Journal:  Clin Immunol       Date:  2006-01-05       Impact factor: 3.969

4.  Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.

Authors:  C R Rinaldo; X L Huang; Z Fan; J B Margolick; L Borowski; A Hoji; C Kalinyak; D K McMahon; S A Riddler; W H Hildebrand; R B Day; J W Mellors
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

Review 6.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

7.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

8.  Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load.

Authors:  Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Anette Stryhn; Catherine Koofhethile; Jacqui Brener; Fabian Chen; Lynn Riddell; Luzzi Graziano; Paul Klenerman; Alasdair Leslie; Søren Buus; David A Price; Philip Goulder
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

9.  CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status.

Authors:  Audrey L Kinter; Margaret Hennessey; Alicia Bell; Sarah Kern; Yin Lin; Marybeth Daucher; Maria Planta; Mary McGlaughlin; Robert Jackson; Steven F Ziegler; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

10.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Authors:  Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  3 in total

Review 1.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

2.  Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.

Authors:  A A Latanova; S Petkov; A Kilpelainen; J Jansons; O E Latyshev; Y V Kuzmenko; J Hinkula; M A Abakumov; V T Valuev-Elliston; M Gomelsky; V L Karpov; F Chiodi; B Wahren; D Y Logunov; E S Starodubova; M G Isaguliants
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

3.  Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes.

Authors:  Tatiana M Garcia-Bates; Mariana L Palma; Renee R Anderko; Denise C Hsu; Jintanat Ananworanich; Bette T Korber; Gaurav D Gaiha; Nittaya Phanuphak; Rasmi Thomas; Sodsai Tovanabutra; Bruce D Walker; John W Mellors; Paolo A Piazza; Eugene Kroon; Sharon A Riddler; Nelson L Michael; Charles R Rinaldo; Robbie B Mailliard
Journal:  EBioMedicine       Date:  2021-01-12       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.